Classic nephropathic or infantile cystinosis (NC) is an autosomal recessive disorder; the gene coding for the integral membrane protein cystinosin, which is responsible for membrane transport of cystine (CTNS), was cloned. Mutation analysis of the CTNS gene of Caucasian patients revealed a common 57-kb deletion, and several other mutations spread throughout the entire gene. In the present study, we report the CTNS mutations identified in 42 of 46 Italian families with NC. The percentage of mutations characterized in this study is 86%. The mutational spectrum of the Italian population is different from that of populations of North European origin: the 57-kb deletion is present in a lower percentage, while the splicing mutations represent 30% of mutation detected in our sample. In all, six novel mutations have been identified, and the origin of one recurrent mutation has been traced.
Introduction
Classic nephropathic or infantile cystinosis (NC) is an autosomal recessive disorder (MIM 219800) causing proximal renal tubular dysfunction because of lysosomal storage of free cystine resulting from impaired transport. 1, 2 It is the most common cause of renal tubular Fanconi syndrome in childhood, and is characterized by failure to thrive, polyuria and polydipsia, dehydration and hypophosphatemic rickets. Affected individuals develop renal failure at about 10 years of age. Patients suffer from a multisystem disease; therapy includes oral intake of free thiol cysteamine, which only slows down the course of the disease, and renal transplantation, which does not eliminate the accumulation of cystine in other organs.
The cystinosis locus was first mapped to a 4-cM region of the short arm of chromosome 17p13 in 1995 by linkage analysis. 3 Subsequent narrowing of this region initially enabled the identification of a deletion of the D17S829 marker and successively the isolation of the cystinosis gene, CTNS, 4 which consists of 12 exons with the first methionine in exon 3. CTNS codes for a 367 amino-acid peptide, cystinosin, predicted to contain seven transmembrane domains (TM). Cystinosin is the lysosomal cystine transporter 5 and it is sorted via a classic tyrosine-based GYDQL lysosomal sorting motif in its C-terminal tail, and a novel conformational lysosomal sorting motif in the fifth inter-TM loop. 6 Previous studies performed in European-and Americanbased subpopulations of cystinosis patients identified many different mutations spread throughout the entire gene, the most frequent one being a large intragenic deletion that removes the first 10 exons plus a large amount of the upstream sequence. 4,7 -15 We report the CTNS mutations identified in 42 Italian patients with NC, enrolled in the Italian Registry of NC. These data provide a basis for the molecular diagnosis of cystinosis in the Italian population.
Materials and methods
Sources of data on NC patients were: the Italian Cystinosis Registry which includes 46 patients, reported by pediatric nephrology centers and metabolic units; the ITALKID Registry which includes all Italian children with renal insufficiency; the North Italian Transplant Registry, and the Registry of the Bracco pharmaceutical company which provides the patients with free drugs. Only subjects with classical NC, with clinical onset in early childhood, were included in the present study.
All NC patients and their families were asked to participate in this study. A total of 42 patients and their parents and unaffected sibs gave their informed consent.
Blood samples were collected from all study participants, and high molecular weight DNA was obtained from peripheral blood lymphocytes by standard phenol -chloroform extraction.
All DNA samples were initially screened for two previously described large (B57 kb) and small (B13 kb) deletions. CTNS coding exons and their flanking sequences in samples found to be heterozygous for the deletion, or in which the deletion was not detected, were amplified by the polymerase chain reaction (PCR) technique, and screened for mutations by the single-strand conformation polymorphism (SSCP) and the conformation-sensitive gel electrophoresis (CSGE) techniques, using different primers. The laboratory in Padova analyzed 27 samples by SSCP, and the laboratory in Rome analyzed the other 15 by CSGE; all samples in which one laboratory did not identify mutations were then analyzed by the other. To characterize the mutations, each sample displaying an abnormal SSCP/ CSGE band pattern was directly sequenced.
The samples in which no mutations were detected, using SSCP and CSGE techniques, underwent direct DNA sequencing of the entire CTNS coding region and of the promoter region.
Detection of known deletions
PCR was used to identify the intragenic deletions. PCR amplification was perfomed using LDM 1 16 and P11 17 primers. To ascertain the presence of a nondeleted allele, D17S829 primers were also included. The 25 ml reaction mixture contained 1 Â PCR buffer, 1.5 mM MgCl 2 , 200 mM dNTPs, 1 mM of each primer, 1 U Taq polymerase and 500 ng of template DNA. In all, 30 cycles were run, consisting of 941C for 30 s, 551C for 40 s and 721C for 1 min. PCR products were electrophoresed on 7% polyacrylamide mini-gel and visualized by silver staining.
SSCP analysis
SSCP analysis was carried out on coding exons 3 -12 using the primers described by Town et al, 4 except for exons 3, 4, 9, 10 and 12 where the following primers were respectively used:
The amplification products were combined with formamide loading dye, denatured at 951C, and electrophoresed overnight on 8% polyacrylamide gel at 110 -140 V. Bands were visualized by silver staining.
CSGE analysis
CSGE analysis was also carried out on exons 3 -12 according to Ganguly et al 18 as described. 19 Different primers were designed for exons 3, 4 and 6:
CTNS Promoter region
PCR of the CTNS promoter region was performed using the following primers: 5 0 -CATGGAGGCTTCTCGTCTTC-3 0 and 5 0 -CGGCTAGACTTTGGGAGAGG-3 0 (T a ¼ 581C). The 25 ml reaction mixture contained 1 Â PCR buffer, 1.5 mM MgCl 2 , 200 mM dNTPs, 0.5 mM of each primer, 1 U Taq polymerase and 500 ng of template DNA. In all, 35 cycles were run, consisting of 951C for 30 s, 581C for 40 s and 721C for 40 s.
DNA sequencing
The PCR products were purified using the High Pure PCR products Purification kit (Roche), and 30 ng were sequenced using the Big Dye Terminator Cycle Sequencing kit (Perkin-Elmer), following the manufacturer's instructions. The sequencing reactions were run on an ABI 310 Automatic Sequencer (Perkin-Elmer).
Results
Patient information was provided by the collaborating centers and reported in Table 1 . In all, 22 patients were female and 20 male, ranging in age from 2 to 29 years. Of the 42 patients, 21 underwent dialysis between 5 and 13 years of age, and among these 11 underwent transplant between 7 and 13 years of age. Consanguinity was reported for four families only. When known, the geographical origin of the grand parents was also recorded. PCR-based amplification using LDM 1 , P11 and D17S829 primers detected 14 deletions (10 cases of 57 kb and four of 13-kb deletion); nine of 10 large deletions were found in probands from North or Central Italy, while three of four small ones in probands from South Italy. Two patients were homozygous for the 57-kb deletion. SSCP and CSGE analyses were followed by sequencing of samples showing an abnormal band pattern; 15 mutated alleles were identified by SSCP, and 23 by CSGE, for a total detection of 38 mutated alleles.
Regarding the 32 remaining alleles (both alleles in 11 patients, one allele in 10) both techniques failed to detect any mutation.
Even if different conditions of SSCP/CSGE analysis were performed (ie concentration of acrylamide, addition of glycerol, gel length), by using these techniques, we found an unexpectedly low frequency of mutation detection. The 21 patients for whom both techniques failed to detect mutation, in one or both of their alleles, were asked to continue the analysis by sequencing the entire coding region of CTNS gene and the promoter region. All but four (#21, 23, 31 and 42) accepted and sequencing allowed the detection of a further 19 mutated alleles and of the previously described À295G4C substitution in six promoters. 20 Among the 16 different mutations detected, six were novel as reported in Table 2 . The c.861G4A is probably a pathogenic mutation; in fact, although it maintains the amino-acid charge (M287I), it was not observed in normal subjects.
In addition to the mutations, four apparent polymorphisms were identified. Two of these are silent mutations (c.504A4G, already described by Shotelersuk et al, 7 and c.885G4A), while the 329+22G4C is intronic; the c.779T4C causes an amino-acid change (I260T), but all were present in patients who also manifested two pathogenic mutations.
Discussion
Cystinosis is a rare disease because of a lysosomal membrane transporter defect. After the CTNS gene was mapped and cloned, several mutations were identified in European and American patients. 4,7 -15 Some phenotypic correlation has been reported, and disease severity appears correlated to the expression of the gene product cystinosin. 8, 15, 21, 22 Infantile cystinosis is because of a homozygous or compound heterozygous state of deletions or mutations causing truncated protein or involving the TM domains. The 57-kb deletion accounts for about 50% of cystinotic chromosomes in European populations, while a study in French -Canadian patients showed a much lower frequency, reflecting an Irish origin. No hot spots have been observed, although some mutations appear to be common.
Previous studies, however, included heterogeneous groups of patients, and only four were performed in small homogeneous populations (from French -Canada, Brittany, The Netherlands and Switzerland -Germany). The present population study includes most Italian NC patients. Records appear complete, as all possible information sources were consulted: pediatric units, transplant registry and data from the pharmaceutical company offering free drugs to patients. Molecular analysis was performed in 42 of the 46 Italian families who consented to this study.
First, we screened the patients for the deletions. Only 14 chromosomes of 84 (17%) carried a deletion. To explain the high proportion of deletions found in his population, Shotelersuk suggested that the short arm of chromosome 17 might be susceptible to deletions. 7, 23 Our data, as well as the French -Canadians results, in which a much lower proportion of deletions was detected, contrast with this hypothesis, and support the hypothesis that this mutation originated from Northern Europe; 13, 17 indeed, the 57-kb mutation is not widespread in North Italy, while the 13-kb deletion is present mainly in South Italy.
Mutations were then searched using two different methods. If none were detected by one laboratory using SSCP or CSGE as the first procedure, the DNA was analyzed with the alternative method and some different primers in a second screening step.
Screening analysis with the two techniques certainly improved the number of mutations detected in our study: the percentage of mutations characterized is 62% (14 deletions and 38 mutations out of 84 alleles). The entire coding region of 17 patients, for whom both techniques failed to detect any mutation in one or both of their alleles, was sequenced, allowing the identification of a further 19 mutated alleles for a total of 71/84 alleles (84%).
Mutations in the CTNS gene promoter were recently identified and it was suggested that they could partially account for the undetected mutations in the coding sequence. 20 In order to exclude the presence of mutations in the CTNS gene promoter, this regulatory region was also sequenced in patients in which no mutations were detected by SSCP/CSGE analysis, allowing the detection of a previously described À295G4C substitution in five patients, all coming from a small region of Northern Italy (Friuli Venezia Giulia). Four of these carried two other pathological mutations. This observation suggests that more studies are necessary to establish the real pathogenicity of the À295G4C substitution. Interestingly, this promoter base change is always inherited in cis with two polymorphisms (c.329+22G4C and c.779T4C) detected only in these five patients, and with the c.1015G4A in four of them. These findings enable us to define a typical haplotype of the patients coming from the North of the Friuli Venezia Giulia region.
All the data collected demonstrate that the mutational spectrum of the Italian population is different from that of populations of North European origin. 11 -13 In general, the 57-kb deletion is present in a lower percentage, while the splicing mutations are 22/84 -higher than the figures reported in the literature. The recurrent mutation 753G4A (W138X) 9 is not present in Italian patients, while two mutations appear to be frequent in our patients: the c.1015G4A (16 alleles) and the c.681+1G4A (15 alleles) single nucleotide substitutions. The c.1015G4A was identified for the first time in one allele of a compound heterozygous patient of Italian ancestry 7 and recently described as the most common cause of nephropathic cystinosis in the Ontario Amish Mennonite.
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The 16 alleles bearing the c.1015G4A are clustered in two groups, one in Southern and one in Northern Italy, while nine of the 10 patients with the c.681+1G4A come from Southern Italy. The A of the ATG of the initiator Met codon in cDNA is denoted nucleotide +1. 24 b Novel mutation. nt, nucleotide; aa, amino acid.
Mutational spectrum of the CTNS gene S Mason et al
Our data confirm that the mutational spectrum of the CTNS gene is wide; the gene presents few common mutations probably because of founder's effect.
This observation raises the suspicion of parental consanguinity in patients homozygous for a specific mutation, as in our cases #1, 2, 5, 7, 9, 12, 13, 20, 25, 28, 29, 32, 34, 38 and 41. However, the family studies in most cases did not disclose a known parental consanguinity (Table 1) , while surprisingly almost all affected patients reporting consanguinity were genetic compounds. This unexpected finding may be because of an unknown low-degree consanguinity or to a higher frequency of pathogenetic mutations in the CTNS locus.
